metipranolol ophthalmic (Discontinued)

Brand and Other Names:OptiPranolol (DSC)
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

  • 0.3%

Open-Angle Glaucoma

1 gtt in affected eye(s) q12hr

Safety & efficacy not established

Next:

Interactions

Interaction Checker

and metipranolol ophthalmic

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (2)

                • digoxin

                  metipranolol ophthalmic increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.

                • fingolimod

                  metipranolol ophthalmic increases effects of fingolimod by pharmacodynamic synergism. Use Caution/Monitor. Both medications decrease heart rate. Monitor patients on concomitant therapy, particularly in the first 6 hours after fingolimod is initiated or after a treatment interruption of at least two weeks, for bradycardia and atrioventricular block. To identify underlying risk factors of bradycardia and AV block, obtain a new or recent ECG in patients using beta-blockers prior to starting fingolimod.

                Minor (25)

                • acebutolol

                  metipranolol ophthalmic increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • amlodipine

                  metipranolol ophthalmic increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown.

                • atenolol

                  metipranolol ophthalmic increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • betaxolol

                  metipranolol ophthalmic increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • bisoprolol

                  metipranolol ophthalmic increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • carvedilol

                  metipranolol ophthalmic increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown.

                • celiprolol

                  metipranolol ophthalmic increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • clevidipine

                  metipranolol ophthalmic increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown.

                • diltiazem

                  metipranolol ophthalmic increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown.

                • esmolol

                  metipranolol ophthalmic increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • felodipine

                  metipranolol ophthalmic increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown.

                • isradipine

                  metipranolol ophthalmic increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.

                • labetalol

                  metipranolol ophthalmic increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

                • metoprolol

                  metipranolol ophthalmic increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • nadolol

                  metipranolol ophthalmic increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • nebivolol

                  metipranolol ophthalmic increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • nicardipine

                  metipranolol ophthalmic increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.

                • nifedipine

                  metipranolol ophthalmic increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.

                • nisoldipine

                  metipranolol ophthalmic increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.

                • penbutolol

                  metipranolol ophthalmic increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • pindolol

                  metipranolol ophthalmic increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • propranolol

                  metipranolol ophthalmic increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • sotalol

                  metipranolol ophthalmic increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

                • timolol

                  metipranolol ophthalmic increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown.

                • verapamil

                  metipranolol ophthalmic increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Ocular

                • Burning sensation in eye
                • Blepharitis
                • Blurred vision
                • Light intolerance
                • Uveitis
                • Tearing
                • Eyelid dermatitis
                • Browache

                Systemic

                • Similar to systemic beta-blockers including bradycardia, aggravation of CHF, nausea, asthma, nightmares, impotence, tiredness, cough, dyspnea, epistaxis, rhinitis, myalgia, arthritis, rash
                • Reduction of systemic side effects by putting finger in corner of eye (occluding punctum) or by gentle eyelid closure (without opening & closing lid) for 3 min
                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity

                Asthma, uncompensated CHF, severe COPD, symptomatic sinus bradycardia, 2nd or 3rd degree AV block, cardiogenic shock

                Cautions

                Caution in diabetes (may mask signs of hypoglycemia)

                Caution on inadequate cardiac function, latent cardiac insufficiency, cerebrovascular insufficiency, sick sinus syndrome, peripheral vascular disease, history of psychiatric illness, heart failure, diminished pulmonary function, nonallergic bronchospasm, diabetes mellitus, myasthenia gravis

                Patients receiving topical levobunolol & a systemic ß-adrenergic blocking agent concomitantly should be observed carefully for potential additive effects on IOP &/or systemic effects of ß-adrenergic blockade

                May mask signs of hyperthyroidism (ie, tachycardia)

                Remove contact lens prior to administration

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: C

                Lactation: Excretion in breast milk unknown; use caution

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Nonselective beta-adrenergic receptor blocker; lacks intrinsic sympathomimetic activity and membrane stabilizing effects; reduces IOP by reducing production of aqueous humor

                Pharmacokinetics

                Onset of action: <30 min

                Peak effect: ~2 hr

                Half-life: 3 hr

                Duration: Up to 24 hr (intraocular pressure reduction)

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.